Love Employee/iStock via Getty Images Datopotamab deruxtecan, an antibody drug conjugate under development from AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo ( OTCPK:DSKYF ), did not significantly improve overall survival in a phase 3 non-small cell lung cancer trial. Patients enrolled in the trial has locally advanced or metastatic NSCLC who were treated with at least one prior therapy. The companies did say, however, that in a subset of patients with nonsquamous NSCLC, "datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel.
" The results are a setback for AstraZeneca and Daiichi Sankyo ( OTCPK:DSNKY ), especially considering earlier results from the TROPION-Lung01 trial, which previously met the dual primary endpoint, progression-free survival. Datopotamab deruxtecan is presently under review by the U.S.
FDA and European Medicines Agency for locally advanced or metastatic nonsquamous NSCLC in patients who have received prior systemic therapy. It has a Dec. 20 FDA action date .
More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market Nona Biosciences and AstraZeneca sign global license and option agreement AstraZeneca projects $80B in revenue by 2030.
